Scientific Publications by FDA Staff
J Infect Dis 2006 Feb 15;193(4):598-600
1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
Ivanov AP, Dragunsky EM, Chumakov KM
Ivanov AP, 1401 Rockville Pike,HFM-470, Rockville, MD 20852 USA US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPVs.
|Category: Journal Article|
|PubMed ID: #16425140|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-04||Entry Last Modified: 2012-08-29|